---
title: SGLT2 Inhibitors in Diabetic Kidney Disease
date: "2023-01-22"
enableToc: false
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[Huppert's Notes]]

# SGLT2 Inhibitors in Diabetic Kidney Disease #ðŸš§ æ–½å·¥ä¸­

### SGLT2 Inhibitors in Diabetic Kidney Disease

â€¢Â Â Â **CREDENCE.** *N Eng J Med* 2019;380(24):2295â€“2306.

-Â Â Â Prospective, double-blind, randomized controlled trial that randomized patients with DM2, albuminuria, and reduced GFR to the SGLT2 inhibitor canagliflozin or placebo. Canagliflozin 100 mg/day reduced risk of kidney failure and cardiovascular events among these patients.

